The in vitro antifungal susceptibilities of 159 clinical isolates of Candida species from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia, were determined against amphotericin B, fluconazole, voriconazole, itraconazole and caspofungin. The most common species were Candidaalbicans (71 isolates), Candida parapsilosis (42 isolates), Candida tropicalis (27 isolates) and Candida glabrata (12 isolates). The susceptibility tests were carried out using an E-test. The MIC breakpoints were based on Clinical Laboratory Standards Institute criteria. Amphotericin B and voriconazole showed the best activities against all the isolates tested, with MIC90 values of ≤1 µg ml−1 for all major species. Only one Candida lusitaniae isolate was resistant to amphotericin B, and all the isolates were susceptible to voriconazole. In total, six isolates were resistant to fluconazole, comprising two isolates of C. albicans, two of C. parapsilosis, one C. tropicalis and one C. glabrata, and all of these isolates showed cross-resistance to itraconazole. The MIC90 of itraconazole was highest for C. glabrata and C. parapsilosis. Caspofungin was active against most of the isolates except for five isolates of C. parapsilosis. The MIC90 of caspofungin against C. parapsilosis was 3 µg ml−1. In conclusion, amphotericin B remains the most active antifungal agent against most Candida species except for C. lusitaniae. Voriconazole is the best alternative for fluconazole- or itraconizole-resistant isolates. Although five of the C. parapsilosis isolates showed in vitro resistance to caspofungin, more clinical correlation studies need to be carried out to confirm the significance of these findings. Currently, despite the increase in usage of antifungals in our hospitals, especially in the management of febrile neutropenia patients, the antifungal-resistance problem among clinically important Candida isolates in Kuala Lumpur Hospital is not yet worrying. However, continued antifungal-susceptibility surveillance needs to be conducted to monitor the antifungal-susceptibility trends of Candida species and other opportunistic fungal pathogens.
AnaissieE. J.,
PaetznickV. L.,
EnsignL. G.,
Espinel-IngroffA.,
GalgianiJ. N.,
HitchcockC. A.,
LaRoccoM.,
PattersonT.,
PfallerM. A. et al.1996; Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcusneoformans with and without agitation: an eight-center collaborative study. Antimicrob Agents Chemother 40:2387–2391[PubMed]
BodeyG. P.,
MardaniM.,
HannaH. A.,
BoktourM.,
AbbasJ.,
GirgawyE.,
HachemR. Y.,
KontoyiannisD. P.,
RaadI. I.2002; The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112:380–385 [View Article][PubMed]
CheungC.,
GuoY.,
GialanellaP.,
FeldmesserM.2006; Development of candidemia on caspofungin therapy: a case report. Infection 34:345–348 [View Article][PubMed]
ChongP. P.,
LeeY. L.,
TanB. C.,
NgK. P.2003; Genetic relatedness of Candida strains isolated from women with vaginal candidiasis in Malaysia. J Med Microbiol 52:657–666 [View Article][PubMed]
EdmondM. B.,
WallaceS. E.,
McClishD. K.,
PfallerM. A.,
JonesR. N.,
WenzelR. P.1999; Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:239–244 [View Article][PubMed]
KaoA. S.,
BrandtM. E.,
PruittW. R.,
ConnL. A.,
PerkinsB. A.,
StephensD. S.,
BaughmanW. S.,
ReingoldA. L.,
RothrockG. A. et al.1999; The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 29:1164–1170 [View Article][PubMed]
MokaddasE. M.,
Al-SweihN. A.,
KhanZ. U.2007; Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 56:255–259 [View Article][PubMed]
Mora-DuarteJ.,
BettsR.,
RotsteinC.,
ColomboA. L.,
Thompson-MoyaL.,
SmietanaJ.,
LupinacciR.,
SableC.,
KartsonisN. et al.2002; Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029 [View Article][PubMed]
Ostrosky-ZeichnerL.,
RexJ. H.,
PappasP. G.,
HamillR. J.,
LarsenR. A.,
HorowitzH. W.,
PowderlyW. G.,
HyslopN.,
KauffmanC. A. et al.2003; Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–3154 [View Article][PubMed]
PfallerM. A.,
JonesR. N.,
DoernG. V.,
SaderH. S.,
HollisR. J.,
MesserS. A.forThe SENTRY Participant Group1998a; International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 36:1886–1889[PubMed]
PfallerM. A.,
JonesR. N.,
MesserS. A.,
EdmondM. B.,
WenzelR. P.1998b; National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic Importance. Diagn Microbiol Infect Dis 30:121–129[CrossRef]
PfallerM. A.,
DiekemaD. J.,
RinaldiM. G.,
BarnesR.,
HuB.,
VeselovA. V.,
TiraboschiN.,
NagyE.,
GibbsD. L.2005; Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 43:5848–5859 [View Article][PubMed]
PfallerM. A.,
BoykenL.,
HollisR. J.,
MesserS. A.,
TendolkarS.,
DiekemaD. J.2006; In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 44:760–763[CrossRef]
PfallerM. A.,
BoykenL.,
HollisR. J.,
KroegerJ.,
MesserS. A.,
TendolkarS.,
DiekemaD. J.2008; In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46:150–156 [View Article][PubMed]
Rangel-FraustoM. S.,
WiblinT.,
BlumbergH. M.,
SaimanL.,
PattersonJ.,
RinaldiM.,
PfallerM.,
EdwardsJ. E.Jr,
JarvisW. et al.1999; National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29:253–258 [View Article][PubMed]
RexJ. H.,
PfallerM. A.,
GalgianiJ. N.,
BartlettM. S.,
Espinel-IngroffA.,
GhannoumM. A.,
LancasterM.,
OddsF. C.,
RinaldiM. G. et al.1997; Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 24:235–247 [View Article][PubMed]